Theravance Biopharma, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Theravance Biopharma, Inc. (TBPH) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$32.70 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-01.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2024-03-01
- Theravance Biopharma, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2023-12-31 was -$677.00K, a 101.73% decline year-over-year.
- Theravance Biopharma, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2023-09-30 was -$21.00K.
- Theravance Biopharma, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2023-06-30 was $11.05M, a 47.00% increase year-over-year.
- Theravance Biopharma, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2023-03-31 was -$43.05M, a 234.84% decline year-over-year.
- Theravance Biopharma, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2023 was -$32.70M, a 155.54% decline from fiscal 2022.
- Theravance Biopharma, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2022 was $58.88M, a 52.71% decline from fiscal 2021.
- Theravance Biopharma, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2021 was $124.49M, a 1061.22% increase from fiscal 2020.
- Theravance Biopharma, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2020 was $10.72M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$677.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$698.00K derived: sum of 2 quarters · filed 2024-03-01 | $10.35M derived: sum of 3 quarters · filed 2024-03-01 | -$32.70M 10-K · filed 2024-03-01 |
| 2023-09-30 | -$21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $11.03M derived: sum of 2 quarters · filed 2023-11-09 | -$32.02M 10-Q · filed 2023-11-09 | $7.14M derived: sum of 4 quarters · filed 2024-03-01 |
| 2023-06-30 | $11.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$32.00M 10-Q · filed 2023-08-09 | $7.16M derived: sum of 3 quarters · filed 2024-03-01 | -$12.56M derived: sum of 4 quarters · filed 2024-03-01 |
| 2023-03-31 | -$43.05M 10-Q · filed 2023-05-10 | -$3.88M derived: sum of 2 quarters · filed 2024-03-01 | -$23.61M derived: sum of 3 quarters · filed 2024-03-01 | -$16.09M derived: sum of 4 quarters · filed 2024-03-01 |
| 2022-12-31 | $39.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $19.44M derived: sum of 2 quarters · filed 2024-03-01 | $26.95M derived: sum of 3 quarters · filed 2024-03-01 | $58.88M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$19.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$12.21M derived: sum of 2 quarters · filed 2023-11-09 | $19.71M 10-Q · filed 2023-11-09 | $30.54M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $7.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $39.44M 10-Q · filed 2023-08-09 | $50.26M derived: sum of 3 quarters · filed 2023-08-09 | |
| 2022-03-31 | $31.92M 10-Q · filed 2023-05-10 | $42.75M derived: sum of 2 quarters · filed 2023-05-10 | ||
| 2021-12-31 | $10.82M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $124.49M 10-K · filed 2023-03-01 | ||
| 2021-09-30 | $113.67M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $10.72M 10-K · filed 2023-03-01 | |||
| 2017-03-31 | -$123.52M 10-Q · filed 2017-05-10 | -$169.73M derived: sum of 2 quarters · filed 2017-05-10 | -$219.57M derived: sum of 3 quarters · filed 2017-05-10 | -$288.14M derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-12-31 | -$46.20M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$96.05M derived: sum of 2 quarters · filed 2017-03-01 | -$164.62M derived: sum of 3 quarters · filed 2017-03-01 | -$148.24M 10-K · filed 2017-03-01 |
| 2016-09-30 | -$49.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$118.42M derived: sum of 2 quarters · filed 2016-11-09 | -$102.03M 10-Q · filed 2016-11-09 | -$136.53M derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-06-30 | -$68.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$52.19M 10-Q · filed 2016-08-09 | -$86.69M derived: sum of 3 quarters · filed 2017-05-10 | -$24.60M derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-03-31 | $16.39M 10-Q · filed 2017-05-10 | -$18.12M derived: sum of 2 quarters · filed 2017-05-10 | $43.97M derived: sum of 3 quarters · filed 2017-05-10 | $85.27M derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-31 | -$34.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $27.59M derived: sum of 2 quarters · filed 2017-03-01 | $68.89M derived: sum of 3 quarters · filed 2017-03-01 | $111.04M 10-K · filed 2017-03-01 |
| 2015-09-30 | $62.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $103.39M derived: sum of 2 quarters · filed 2016-11-09 | $145.54M 10-Q · filed 2016-11-09 | $155.23M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $41.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $83.45M 10-Q · filed 2016-08-09 | $93.14M derived: sum of 3 quarters · filed 2017-03-01 | -$16.72M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $42.15M 10-Q · filed 2016-05-10 | $51.84M derived: sum of 2 quarters · filed 2017-03-01 | -$58.02M derived: sum of 3 quarters · filed 2017-03-01 | -$62.48M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $9.68M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$100.17M derived: sum of 2 quarters · filed 2017-03-01 | -$104.63M derived: sum of 3 quarters · filed 2017-03-01 | -$106.25M 10-K · filed 2017-03-01 |
| 2014-09-30 | -$109.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$114.31M derived: sum of 2 quarters · filed 2015-11-12 | -$115.94M 10-Q · filed 2015-11-12 | -$117.00M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-06-30 | -$4.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | -$6.08M 10-Q · filed 2015-08-13 | -$7.14M derived: sum of 3 quarters · filed 2016-03-11 | -$7.38M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-03-31 | -$1.62M 10-Q · filed 2015-05-13 | -$2.69M derived: sum of 2 quarters · filed 2016-03-11 | -$2.92M derived: sum of 3 quarters · filed 2016-03-11 | -$3.61M derived: sum of 4 quarters · filed 2016-03-11 |
| 2013-12-31 | -$1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | -$1.30M derived: sum of 2 quarters · filed 2016-03-11 | -$1.99M derived: sum of 3 quarters · filed 2016-03-11 | -$2.63M 10-K · filed 2016-03-11 |
| 2013-09-30 | -$237.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | -$928.00K derived: sum of 2 quarters · filed 2014-11-12 | -$1.57M 10-Q · filed 2014-11-12 | |
| 2013-06-30 | -$691.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | -$1.33M 10-Q · filed 2014-08-14 | ||
| 2013-03-31 | -$640.00K 10-Q · filed 2014-06-24 | |||
| 2012-12-31 | -$2.43M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |